<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02538627</url>
  </required_header>
  <id_info>
    <org_study_id>MM-151-01-01-02</org_study_id>
    <nct_id>NCT02538627</nct_id>
  </id_info>
  <brief_title>Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib</brief_title>
  <official_title>A Phase 1 Multi Arm Study Evaluating the Safety, Pharmacology and Preliminary Activity of the Co-Administration of MM-151 With Seribantumab (MM-121), Istiratumab (MM-141), or Trametinib in Biomarker-selected Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merrimack Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merrimack Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      This is a Phase 1 open-label, dose-escalation trial using &quot;3+3&quot; design, evaluating MM-151
      co-administration with MM-121, MM-141, and trametinib at varying dose levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-part Phase 1, non-randomized, open-label study of MM-151 plus MM-121, MM-141,
      or trametinib in patients with advanced, heregulin-positive lung, head and neck, and
      colorectal cancers. In part 1 of the study, cohorts of 3 or more patients will be treated at
      escalating doses of MM-151 in combination with MM-121, MM-141, and trametinib until a maximum
      tolerated combination dose for each combination is identified. In part 2 of the study,
      patients will be treated with the combination dose identified in part 1 of the study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision
  </why_stopped>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">October 5, 2016</completion_date>
  <primary_completion_date type="Actual">October 5, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To find a phase II dose of MM-151 in combination with MM-121, MM-141, and trametinib based on maximum tolerated dose (MTD) in patients with lung, head and neck, and colorectal cancers</measure>
    <time_frame>1.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of dose limiting toxicities (DLTs) within a group</measure>
    <time_frame>1.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event profile of MM-151 in combination with MM-121, MM-141, and trametinib</measure>
    <time_frame>1.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response to MM-151 in combination with MM-121, MM-141, and trametinib based on RECIST</measure>
    <time_frame>1.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>MM-151+MM-121 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MM-151 and MM-121 dose escalation in lung, head and neck, and colorectal cancers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MM-151+ trametinib Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MM-151 and trametinib dose escalation in lung, head and neck, and colorectal cancers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MM-151+MM-141 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MM-151 and MM-141 dose escalation in lung, head and neck, and colorectal cancers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MM-151+trametinib Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MM-151 and trametinib dose escalation in lung, head and neck, and colorectal cancers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colorectal cancer Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doses established in part 1 of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Head and neck Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doses established in part 1 of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MM-151</intervention_name>
    <description>MM-151</description>
    <arm_group_label>MM-151+MM-121 Dose Escalation</arm_group_label>
    <arm_group_label>MM-151+ trametinib Dose Escalation</arm_group_label>
    <arm_group_label>MM-151+MM-141 Dose Escalation</arm_group_label>
    <arm_group_label>MM-151+trametinib Dose Escalation</arm_group_label>
    <arm_group_label>Colorectal cancer Expansion</arm_group_label>
    <arm_group_label>Head and neck Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MM-121</intervention_name>
    <description>MM-121</description>
    <arm_group_label>MM-151+MM-121 Dose Escalation</arm_group_label>
    <arm_group_label>Colorectal cancer Expansion</arm_group_label>
    <arm_group_label>Head and neck Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MM-141</intervention_name>
    <description>MM-141</description>
    <arm_group_label>MM-151+MM-141 Dose Escalation</arm_group_label>
    <arm_group_label>Colorectal cancer Expansion</arm_group_label>
    <arm_group_label>Head and neck Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trametinib</intervention_name>
    <description>trametininb</description>
    <arm_group_label>MM-151+ trametinib Dose Escalation</arm_group_label>
    <arm_group_label>MM-151+trametinib Dose Escalation</arm_group_label>
    <arm_group_label>Colorectal cancer Expansion</arm_group_label>
    <arm_group_label>Head and neck Expansion</arm_group_label>
    <other_name>MEKINIST</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be &gt;18 years of age

          -  Patients must be able to provide informed consent

          -  Willing to abstain from sexual intercourse or to use an effective form of
             contraception during the study and for 90 days following the last dose of any study
             therapy). This applies to women of childbearing potential as well as fertile men and
             their partners

          -  Patients must be recovered from the effects of any prior surgery, radiotherapy or
             other antineoplastic therapy, up to CTCAE grade 1

          -  Patients must have either heregulin-positive cancer, cancer with RAS mutation, IGF-1
             positive cancer, or RAS wild type cancer.

        Exclusion Criteria:

          -  Patients who are pregnant or lactating

          -  Patients who have an active infection or with an unexplained fever &gt; 38.5Â°C during
             screening visits or on the first scheduled day of dosing (at the discretion of the
             investigator, patients with tumor fever may be enrolled.)

          -  Patients with untreated (primary) or symptomatic CNS (primary or metastatic)
             malignancies; patients with CNS metastases who have undergone surgery or radiotherapy
             or who have been on a stable dose of corticosteroids for at least 2 weeks and whose
             disease is stable prior to the first scheduled day of dosing will be eligible for the
             trial.

          -  Patients who have received other recent antitumor therapy including any standard
             chemotherapy or radiation within 14 days (and having passed the time of any actual or
             anticipated toxicities) prior to the first scheduled dose of the study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2015</study_first_submitted>
  <study_first_submitted_qc>August 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2015</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heregulin-positive</keyword>
  <keyword>EGFR</keyword>
  <keyword>ErbB3</keyword>
  <keyword>Phase I</keyword>
  <keyword>Oncology</keyword>
  <keyword>Cancer</keyword>
  <keyword>IGF-1</keyword>
  <keyword>MEKinhibitor</keyword>
  <keyword>IGF-1R inhibitor</keyword>
  <keyword>KRAS</keyword>
  <keyword>NRAS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

